Cosmetics Personal Care
Safety by design. No animal testing.
The EU cosmetics ban on animal testing didn't lower the safety bar — it removed one of the tools for clearing it. Every core Biobide assay is classified as a New Approach Methodology up to 120 hpf under EU Directive 2024/1262, and our Level 3 endocrine disruption screen — EASZY, OECD TG 250 — is validated at 100% accuracy, sensitivity and specificity, built to sit inside SCCS and REACH-aligned ingredient dossiers.
Selected clients in this space: L'Oréal
Why formulation teams screen here first
Systemic signal, not just a cellular one
Compliant by design, not by exception
Every core assay runs before 120 hpf — inside the NAM classification set by EU Directive 2024/1262, outside the scope of any mammalian-testing question a regulator or a retailer might raise.
Catches what single-target panels miss
Cardiac rhythm, liver opacity and locomotor behaviour are whole-organism readouts — signals a receptor-binding assay or a 2D cell line simply doesn't generate.
A validated Level 3 endocrine disruption screen
EASZY holds 100% accuracy, sensitivity and specificity as an OECD TG 250 estrogenic assay — evidence built to stand inside an SCCS submission, not a screening-only claim.
Built for a library, not one SKU
24- and 96-well plate compatibility means testing ten reformulations costs time, not a proportional multiple of it.
Relevant from the catalogue
Assays this industry books most
What an ingredient safety dossier typically pulls from the catalogue.
Systemic & Developmental Toxicology
TERATOTOX, HEPATOTOX, CARDIOTOX, NEUROTOX
NAM, <120 hpf · View assays →
Genotoxicity
Ames, micronucleus, chromosomal aberration
View assays →
Endocrine Disruption Screening
EASZY & ZETA
OECD TG 250 · View assays →
Technology Platform
High-content screening for ingredient libraries
HCS · View assays →
Regulatory context
The testing approach is built around the EU Cosmetics Regulation's animal-testing ban — NAM-classified zebrafish embryo assays under EU Directive 2024/1262, paired with the standard in vitro genotoxicity methods SCCS and REACH-aligned ingredient dossiers already rely on.
Screening a new ingredient or a reformulation
Send the ingredient list and we'll put together a NAM-based safety battery — no mammalian testing, no compliance question left open.
